(Q35629109)

9 August 2017

1 reference

title

Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis (English)

1 reference

9 August 2017

1 reference

1

Loftus EV Jr

1 reference

9 August 2017

Kane SV

2

1 reference

9 August 2017

Bjorkman D

series ordinal

3

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

Alimentary Pharmacology & Therapeutics

9 August 2017

published in

1 reference

9 August 2017

volume

19

1 reference

9 August 2017

issue

2

1 reference

9 August 2017

page(s)

179-189

1 reference

Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.0269-2813.2004.01827.X

Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0269-2813.2004.01827.X

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0269-2813.2004.01827.X

Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0269-2813.2004.01827.X

Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0269-2813.2004.01827.X

A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0269-2813.2004.01827.X

A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0269-2813.2004.01827.X

A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0269-2813.2004.01827.X

Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0269-2813.2004.01827.X

Adverse events in patients treated with 5-aminosalicyclic acid: 1993-1994 pharmacovigilance report for Pentasa in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0269-2813.2004.01827.X

Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0269-2813.2004.01827.X

10.1111/J.0269-2813.2004.01827.X

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference